Lupin Tofakin Tablet ER contains Tofacitinib 11 mg, an extended-release formulation of a Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional therapies. Tofacitinib exerts its therapeutic effect by selectively inhibiting JAK enzymes, thereby modulating the signaling pathways involved in the pathogenesis of inflammatory and autoimmune conditions. The extended-release formulation allows for once-daily dosing, improving patient adherence and maintaining consistent plasma drug concentrations. Clinical studies have demonstrated that Tofacitinib effectively reduces signs and symptoms, inhibits structural joint damage, and improves physical function in rheumatoid arthritis patients. It also helps achieve and maintain clinical remission in ulcerative colitis and reduces the symptoms of psoriatic arthritis. Common adverse effects include upper respiratory tract infections, headache, and gastrointestinal disturbances. Serious risks involve infections, malignancies, and thrombosis; therefore, patients require regular monitoring, including complete blood counts, liver function tests, and lipid profiles. Lupin Tofakin Tablet ER should be prescribed and administered under specialist supervision, with careful consideration of contraindications such as active infections and hypersensitivity to the active ingredient.